지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2010.1
- 수록면
- 12 - 17 (6page)
이용수
초록· 키워드
오류제보하기
Purpose :To assess the efficacy and safety of treating Korean patients with metastatic hormonerefractory prostate cancer (HRPC) using docetaxel plus prednisolone chemotherapy.
Materials and Methods :This was a retrospective cohort study performed in 98 patients with metastatic HRPC between October 2003 and April 2008. After screening, 72 patients fit the eligibility criteria for inclusion in this study. Treatment consisted of 5 mg prednisolone twice daily and 75 mg/m2 docetaxel once every 3 weeks.
Results :Patient demographic characteristics included: median age 67 years (range, 51∼86), median ECOG performance status 1 (0∼2), Gleason score ≥8 in 61 patients (86%), and median serum PSA 45.5 ng/mL (range, 3.7∼2,420.0). A total of 405 cycles of treatment were administered with a median 6 cycles (range, 1∼20) per patient. The median docetaxel doseintensity was 24.4 mg/m2/week (range, 17.5∼25.6). A PSA response was seen in 51% of 63 evaluable patients at 12 weeks and maximal PSA decline ≥50% in 59% of 70 evaluable patients. Tumor response was evaluated in 13 patients, 4 patients achieved PR, and 5 patients had SD with a response rate of 31%. With a median follow-up duration of 23.1 months (95%CI, 16.7∼29.5), the median time to PSA progression was 5.1 months (95%CI, 4.5 ∼5.8) and median overall survival was 22.8 months (95%CI, 16.6∼29.1). Nine (13%) patients experienced grade 3 or higher febrile neutropenia.
Conclusion :This chemotherapy regimen (docetaxel every 3 weeks plus prednisolone daily) demonstrated a strong response in Korean patients with metastatic HRPC, while the toxicity profile was manageable and similar to that observed in Western patients.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
[학술지(정기간행물
Attard G / 2009 / Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer / J Clin Oncol 27 : 3742 ~
Berthold DR / 2008 / Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study / J Clin Oncol 26 : 242 ~
Clarke SJ / 1999 / Clinical pharmacokinetics of docetaxel / Clin Pharmacokinet 36 : 99 ~ 114
Di Lorenzo G / 2007 / Hormone-refractory prostate cancer: where are we going? / Drugs 67 : 1109 ~ 1124
Attard G / 2009 / Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer / J Clin Oncol 27 : 3742 ~
Berthold DR / 2008 / Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study / J Clin Oncol 26 : 242 ~
Clarke SJ / 1999 / Clinical pharmacokinetics of docetaxel / Clin Pharmacokinet 36 : 99 ~ 114
Di Lorenzo G / 2007 / Hormone-refractory prostate cancer: where are we going? / Drugs 67 : 1109 ~ 1124
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Docetaxel and Cisplatin Combination Chemotherapy in Patients with Squamous Cell Carcinomas of the Head and Neck
Cancer Research and Treatment
2003 .01
-
Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer:Comparative Analysis between 1st-line and 2nd-line Docetaxel
Yonsei Medical Journal
2008 .01
-
Efficacy and Safety Study of Docetaxel as Salvage Chemotherapy in Metastatic Gastric Cancer Failing Fluoropyrimidine and Platinum Combination Chemotherapy
Cancer Research and Treatment
2005 .01
-
The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated With Platinum-based Chemotherapy
Cancer Research and Treatment
2005 .01
-
Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer
Cancer Research and Treatment
2007 .01
-
Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer
Asian Pacific journal of cancer prevention : APJCP
2014 .01
-
Phase II Study of Docetaxel and Cisplatin as First-line Chemotherapy in Patients with Recurrent or Metastatic Gastric Cancer
Cancer Research and Treatment
2007 .01
-
Induction Chemotherapy of Docetaxel and Cisplatin for the Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
Cancer Research and Treatment
2007 .01
-
진행성 비소세포폐암의 이차항암화학요법으로서 Docetaxel 단독요법의 성적
Tuberculosis and Respiratory Diseases
2005 .01
-
Efficacy and Safety of Trastuzumab Added to Standard Treatments for HER2-positive Metastatic Breast Cancer Patients
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
Burnt-out Metastatic Prostate Cancer
영남의대학술지
2013 .01
-
Therapeutic Regimens and Prognostic Factors of Brain Metastatic Cancers
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
Opposing Effects of Prednisolone Treatment on T/NKT Cell- and Hepatotoxin-Mediated Hepatitis in Mice
한국실험동물학회 학술발표대회 논문집
2014 .02
-
Effect of Combination Chemotherapy with Docetaxel Plus Cisplatin in Patients with Advanced Non-Small Cell LungCancer
Cancer Research and Treatment
2003 .01
-
First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer
Asian Pacific journal of cancer prevention : APJCP
2014 .01
-
Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment
Cancer Research and Treatment
2011 .01
-
Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy
Cancer Research and Treatment
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0